HORIZON-HLTH-2024-DISEASE-03-08-two-stage
HORIZON-HLTH-2024-DISEASE-03-08-two-stage
Programme: Horizon Europe
7 projects · €55,655,209 total EU contribution (project-level) · 120 participating organizations · 28 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€55,655,209
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (14)
- Spain (14)
- Italy (11)
- France (9)
- BE (8)
- NO (8)
- PL (7)
- UK (6)
- AT (5)
- Netherlands (5)
- AU (3)
- CH (3)
- PT (3)
- US (3)
- BR (2)
- EE (2)
- FI (2)
- IE (2)
- IL (2)
- SE (2)
- SI (2)
- AR (1)
- CZ (1)
- DK (1)
- EL (1)
- LT (1)
- PE (1)
- UA (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- INSERM2 projects · FR
- KI2 projects · SE
- UKE2 projects · DE
- UZH2 projects · CH
- UNIVERSITY OF WARWICK2 projects · UK
- ABACUS1 projects · IT
- Breast Cancer Trials, Australia and New Zealand1 projects · AU
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1 projects · FR
- AEGEE-EUROPE1 projects · BE
- INSTITUT JULES BORDET1 projects · BE
- ASL ROMA 61 projects · IT
- BIU1 projects · IL
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
EARLY COLORECTAL CANCER: PATIENT-TARGETED AND ORGAN PRESERVING TREATMENT ECOPOP ECOPOP · 101156165 | HORIZON | €6,999,931 | €0 | Details |
Bridging Gaps in Mental Health Support: A Comprehensive European Strategy YOUTHreach · 101156514 | HORIZON | €8,501,477 | €0 | Details |
IMPROVing lifElong health and development for children and adults born very PRETERM – observational studies to enhance randomised trials for comparative effectiveness research IMPROVE PRETERM · 101156325 | HORIZON | €7,668,748 | €0 | Details |
Personalized Adjuvant Treatment for HR+/HER2- breast cancer FOR YOUNG patients PATH-FOR-YOUNG · 101156800 | HORIZON | €9,498,604 | €0 | Details |
SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION (SGLT2-HYPE) SGLT2-HYPE · 101156555 | HORIZON | €6,999,999 | €0 | Details |
Fighting Addictions, improving Lives: COmprehensive drug rehabilitation with music FALCO · 101155881 | HORIZON | €8,995,781 | €0 | Details |
Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE EAST-STROKE · 101156541 | HORIZON | €6,990,669 | €0 | Details |